Welcome and Introductions
Module 1: Advances in Antibody-drug Conjugates for the Management of HR+/HER2- mBC
Module 2: Applying New Data in ADCs for HER2+ Metastatic Breast Cancer Management
Module 3: Integrating Emerging Data for ADCs in the Management of Metastatic Triple Negative Breast Cancer (TNBC)
Evidence-Based Summary, Post-session Questions, and Audience Q&A
Adjourn